Human Genome Sciences, Inc. (HGSI), Monday said that it has commenced an underwritten public offering of up to 12.50 million shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 1.87 million shares of the company's common stock.
Net proceeds from this offering is expected to use for general corporate purposes, including acquisition of additional manufacturing capacity and development of new indications for BENLYSTA, as well as potential sales and marketing activities, clinical trial, research and development, general and administrative and manufacturing expenses and the potential retirement of debt. The company will also use a portion of the proceeds for strategic investments.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.